Alnylam Announces 33% Staff Cut, Will Focus Internally On Two Lead RNAi Programs
This article was originally published in The Pink Sheet Daily
The RNA interference pioneer will focus on two candidates, ALN-TTR02 for transthyretin-mediated amyloidosis and ALN-APC for hemophilia, while seeking partners for its other “5x15” programs.
You may also be interested in...
The RNA interference-focused biotech will bring the rest of its pipeline forward with subcutaneous technology now that it has been validated in human studies, but the company will continue to pursue approval of its lead candidate as an infusion product.
Building on the 10-pharma clinical development problem-solving initiative launched in September, J&J, Merck and Lilly are spearheading a databank that will share information on clinical trial sites and investigators, with a primary goal of avoiding redundancy in paperwork and training.
RNAi pioneer Alnylan is partnering its transthyretin-mediated amyloidosis program with Genzyme in Japan and Asia-Pacific, while planning to keep rest-of-world rights to the program in-house.